Clinical Trials Browser

Phase 3 × Stomach Neoplasms × nimotuzumab × Clear all

NCT01813253 2018-03-26

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms